AstraZeneca stock gains as Deutsche Bank raises its target

Published on 09/22/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock traded at GBP 126.34 on September 22, 2026, up 0.59 percent in London. Deutsche Bank raised its target to 117p after a negative trial update.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca PLC (ISIN GB0009895292) traded at GBP 126.34 on the London Stock Exchange on September 22, 2026, up 0.59 percent from the previous close of GBP 125.60. The move followed a revised Deutsche Bank assessment, which raised its price target from 11,500p to 11,700p while upgrading the rating from Sell to Hold.

Deutsche Bank turns more cautious

According to Sharecast on September 15, 2026, Deutsche Bank said the risk reward profile had shifted after the negative SERENA-4 readout and a period of underperformance against European large cap peers. The change was therefore not a broad bullish call: the bank moved AstraZeneca from Sell to Hold, while lifting the target by 200p.

The rating change gives the current price a clear valuation reference. At GBP 126.34, the London quote stood 8.03 percent above Deutsche Bank's new target of GBP 117.00, making the broker's revised view more cautious than the same day's market price.

Revenue reached GBP 58.7 billion

Reuters financial data identify AstraZeneca as a United Kingdom based biopharmaceutical company with oncology, cardiovascular, renal and metabolic, respiratory and immune, vaccine and immune therapy, and rare disease operations. The same data show fiscal year 2025 revenue of GBP 58.739 billion, compared with GBP 54.073 billion in fiscal year 2024, an increase of 8.63 percent.

Fiscal year 2025 net income was GBP 10.225 billion, versus GBP 7.035 billion in fiscal year 2024. Operating cash flow reached GBP 14.575 billion in fiscal year 2025, up from GBP 11.861 billion in fiscal year 2024. These figures place the current valuation discussion alongside a measurable earnings and cash generation comparison.

Stock remains below yearly high

The London share price was GBP 126.34 on September 22, 2026, with reported volume of 167,026 shares and market capitalization of GBP 195.247 billion. The 52 week range extended from GBP 107.84 to GBP 157.30, so the price was GBP 30.96 below the yearly high and GBP 18.50 above the yearly low.

The immediate investment question is the balance between the company's 2025 financial base and clinical execution. The SERENA-4 readout cited by Deutsche Bank is a concrete counter-factor, while the 8.63 percent revenue increase and 45.18 percent net income increase between fiscal years 2024 and 2025 provide the measurable operating context.

London price holds at GBP 126.34

AstraZeneca stock closed the available London market snapshot at GBP 126.34 on September 22, 2026, up 0.59 percent from GBP 125.60, with the quote at least 15 minutes delayed.